Pulmonary Hypertension (PH) is a complex and often misunderstood condition. Despite advancements in diagnostic tools and therapeutic options, it remains a significant cause of morbidity and mortality. This article aims to provide a comprehensive guide to help healthcare professionals better understand and manage PH.
PH is defined as a mean pulmonary arterial pressure ≥25 mmHg at rest, confirmed by right heart catheterization. It is classified into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy. This classification aids in the understanding of disease pathophysiology and guides therapeutic decision-making.
The pathophysiology of PH is multifactorial and involves vasoconstriction, vascular remodeling, and thrombosis in situ. The imbalance between vasoconstrictive and vasodilative substances, along with endothelial dysfunction, leads to increased pulmonary vascular resistance, resulting in right heart failure.
Diagnosis of PH is challenging due to the nonspecific nature of symptoms. A high index of suspicion is required for early detection. An echocardiogram is the initial screening tool, followed by right heart catheterization to confirm the diagnosis. Additional investigations like pulmonary function tests, CT scan, and V/Q scan may be needed based on the suspected etiology.
Management of PH is complex and requires a multidisciplinary approach. It includes general measures, targeted drug therapy, and surgical interventions. Early diagnosis and treatment can significantly improve the prognosis. Patient education and regular follow-up are vital elements of management.
PH is a challenging condition that requires a thorough understanding of its fundamentals for effective management. As healthcare professionals, it is our responsibility to stay abreast with the latest advancements in the field to provide optimal care to our patients. A comprehensive understanding of PH will undoubtedly contribute to better patient outcomes.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation